RAPT — Rapt Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $485.22m
- $316.27m
- 36
- 20
- 93
- 47
Annual income statement for Rapt Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5.04 | 3.81 | 1.53 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 58.3 | 73 | 87.3 | 127 | 136 |
| Operating Profit | -53.2 | -69.2 | -85.8 | -127 | -136 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -51.9 | -69.2 | -83.8 | -117 | -130 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -52.9 | -69.2 | -83.8 | -117 | -130 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -52.9 | -69.2 | -83.8 | -117 | -130 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -52.9 | -69.2 | -83.8 | -117 | -130 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -17.5 | -20.2 | -20.6 | -24.4 | -25.5 |